# The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors

> **NCT03507543** · PHASE1 · COMPLETED · sponsor: **Impact Therapeutics, Inc.** · enrollment: 39 (actual)

## Conditions studied

- Advanced Solid Tumours
- Breast Cancer
- Ovarian Cancer
- Prostate Cancer
- Primary Peritoneal Cancer

## Interventions

- **DRUG:** IMP4297

## Key facts

- **NCT ID:** NCT03507543
- **Lead sponsor:** Impact Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-03
- **Primary completion:** 2020-09-24
- **Final completion:** 2021-03-17
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2021-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03507543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03507543, "The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03507543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*